ID   DU145-TxR/CxR
AC   CVCL_ZX04
DR   cancercelllines; CVCL_ZX04
DR   Wikidata; Q102113779
RX   PubMed=29662635;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:63584; Cabazitaxel.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); ClinVar=VCV001786615; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Brain; UBERON=UBERON_0000955.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_ZX03 ! DU145-TxR
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=29662635; DOI=10.18632/oncotarget.24609;
RA   Machioka K., Izumi K., Kadono Y., Iwamoto H., Naito R., Makino T.,
RA   Kadomoto S., Natsagdorj A., Keller E.T., Zhang J., Mizokami A.;
RT   "Establishment and characterization of two cabazitaxel-resistant
RT   prostate cancer cell lines.";
RL   Oncotarget 9:16185-16196(2018).
//